SRI developed halofantrine for the U.S. Army from 1965 to 1975 as a treatment for drug-resistant malaria. Distributed by the World Health Organization (WHO), the drug has saved countless lives. The Food and Drug Administration (FDA) approved halofantrine as an antimalarial in 1992 under the SmithKline Beecham (now GlaxoSmithKline) brand name, Halfan®.
Malaria treatment: Halofantrine
Read more from SRI
-
SRI appoints Peter Marcotullio as Senior Vice President of Commercialization
SRI bolsters the leadership team to deliver cutting-edge research into commercial products and services, driving growth and innovation across various industries.
-
PARC Forum: How innovation can save the living ocean
SRI, in collaboration with Stanford’s Doerr School of Sustainability, hosted the Monterey Bay Aquarium to discuss ocean conservation.
-
Researchers assess EV industry workforce potential in Northeast Ohio
A new study by SRI examines the readiness of a historic manufacturing base to support the transition to EV battery manufacturing.